• Total operating revenues for 2024 were €23.7 million, compared to €15 million for the same period in 2023. 

• As of March 9, 2025, Ryvu’s cash position was €43.7 million. The strategic reorganization implemented in February 2025 and additional secured funding sources extended the company’s financial runway from Q1 to H2 2026. 

Krakow, Poland – March 13, 2025 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, reports its financials for the 2024 fiscal year. 

Pawel Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics, said: 

– In the past year, we have made significant progress in our clinical and preclinical pipeline. We launched all of the planned Phase II clinical trials of RVU120, our first-in-class CDK8/19 inhibitor. By the end of 2024, we had enrolled almost 100 patients and activated more than 110 clinical sites in Europe and North America. We look forward to essential readouts in mid-2025. We also expect to complete IND/CTA-enabling studies of RVU305, our potentially best-in-class PRMT5 MTA-cooperative inhibitor, in H2 2025. 

Krzysztof Brzózka, Ph.D., Executive Vice President, and Chief Scientific Officer, said: 

– At the beginning of 2025 we announced our dual-pronged preclinical strategy, which has potential to generate multiple oncology medicines. We continue to develop our proprietary ONCO Prime platform, which includes synthetic lethal targets; the platform has already identified several novel targets for KRAS-driven tumors. We are also leveraging our expertise in cancer biology to develop novel ADCs with next-generation payloads, both targeting synthetically lethal and immunocytotoxic mechanisms. 

2024 SUMMARY AND RECENT CORPORATE EVENTS 

RVU120 clinical development plan progress 

• Ryvu successfully launched all four RVU120 Phase II clinical studies planned for 2024: RIVER-52 (monotherapy in AML and HR-MDS), RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis) and REMARK (monotherapy in LR-MDS). 

• As of February 2025, approximately 120 patients have been dosed across all RVU120 Phase II studies. Over 110 clinical sites have been activated. 

• Based on the analysis of RIVER-81 and RIVER-52 data, as well as feedback from advisory boards in February 2025, the Company decided to optimize RVU120 clinical program. RIVER-81 will continue as planned, while enrollment in RIVER-52 has been suspended to focus investment on the other RVU120 development paths. 

• Three Phase II RVU120 studies are progressing as planned: RIVER-81, POTAMI-61, and REMARK. 

• Ryvu emphasizes rapid RVU120 study enrollment and quality data generation in 2025. The next data update is planned in Q2 2025. 

Status of other programs 

• The JASPIS-01 study was initiated in Q4 2024, currently awaiting enrollment of the first patient, which is still expected in Q1 2025. The study will commence at clinical sites in Poland with ongoing efforts to expand to additional EU and non-EU countries.  

• In September 2024, Ryvu decided to advance RVU305, its potentially best-in-class PRMT5 inhibitor, to IND/CTA-enabling studies, which are planned to be completed in H2 2025. 

• Ryvu continues to advance its dual-pronged preclinical discovery and research strategy:  

• ONCO Prime – novel small-molecule precision medicine: as part of its proprietary ONCO Prime platform, Ryvu continues to advance several novel precision oncology targets, including synthetic lethality targets. ONCO Prime combines data from patient-derived cells and isogenic cell lines to discover first-in-class oncology targets in defined patient populations. 

• ADCs (antibody-drug conjugates) with novel payloads: Ryvu continues to develop ADCs with next-generation novel payloads, including synthetically lethal and immuno-mechanisms. Ryvu works on novel ADCs internally and through the existing collaboration with Exelixis (STING-based ADCs). 

Ryvu continues to advance partnerships with Menarini, BioNTech and Exelixis. Ryvu is fully reimbursed for its expenses and has the potential to achieve multiple financial milestones. 

UPCOMING INDUSTRY AND INVESTOR EVENTS 

• BIO EU (Milan, IT), March 17-19: Ryvu will hold partnering and investor meetings. 

• Tumor Models Summit Nordic (Stockholm, SE), April 9-10 – Ryvu will deliver a presentation and host scientific and partnering meetings. 

• AACR Annual Congress (Chicago, IL), April 25-30: Ryvu will present a scientific update and host scientific and partnering meetings. 

• ADC Payload Summit (Boston, MA), May 6-8: Ryvu will deliver a presentation on ADC payloads and host scientific and partnering meetings. 

• EHA Annual Congress (Milan, IT), June 12-15: Ryvu will present clinical data updates. 

2024 FISCAL YEAR FINANCIAL UPDATE 

Cash Position – On December 31, 2024, Ryvu Therapeutics held €52.7 million in cash, cash equivalents, bonds and investment funds, compared to €57.6 million at the end of 2023. On March 9, 2025, Ryvu Therapeutics held €43.7 million in cash, cash equivalents, bonds and investment funds. In addition, the Company has secured approximately €21.8 million in non-dilutive grant funding. 

Operating Revenues – In 2024, Ryvu recognized total operating revenues (including grants) of €23.7 million, compared to €15 million in 2023. 

Operating costs, related primarily to research and development expenditures, excluding the valuation of NodThera shares and non-cash cost of valuation of the Incentive Program for 2024, amounted to €51.1 million, compared to €34.7 million in 2023. 

Net Loss Attributable to Common Shareholders – In 2024, the net loss attributable to common shareholders, excluding the non-cash cost of the Incentive Program, amounted to €24.9 million, compared to €18.5 million in the previous year.